David R. Spigel, MD, FASCO (@davidrspigel) 's Twitter Profile
David R. Spigel, MD, FASCO

@davidrspigel

Chief Scientific Officer at Sarah Cannon Research Institute | Advancing Therapies Through Clinical Research #Oncology #Healthcare #CancerResearch

ID: 260571752

linkhttps://www.scri.com/ calendar_today04-03-2011 04:03:35

96 Tweet

3,3K Takipçi

594 Takip Edilen

David R. Spigel, MD, FASCO (@davidrspigel) 's Twitter Profile Photo
David R. Spigel, MD, FASCO
@davidrspigel

7 months ago

Congratulations Erika Hamilton, MD and Team: Camizestrant,a next-gen oral SERD, v fulvestrant in post-menopausal women with ER+, HER2- ABC (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial - Lancet Oncology Sarah Cannon Docs SCRI Oncology Partners thelancet.com/journals/lanon…